tiprankstipranks
Affimed Appoints New CEO to Bolster Growth
Company Announcements

Affimed Appoints New CEO to Bolster Growth

Affimed (AFMD) has released an update.

Don't Miss our Black Friday Offers:

Affimed N.V., a clinical-stage oncology firm, has announced the appointment of Shawn M. Leland as its new CEO. Leland brings over 15 years of industry experience, having raised substantial capital for biotech companies and led crucial partnerships and licensing deals. His previous role as the interim CEO of ForeBio and his achievements, including a $75M Series D financing round, position him to propel Affimed’s growth and strategic development.

For further insights into AFMD stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyAffimed price target lowered to $4 from $5 at Stifel
TipRanks Auto-Generated NewsdeskAffimed Reports Q3 2024 Financial Results and Updates
TipRanks Auto-Generated NewsdeskAffimed Faces Growing Losses Amid Financial Struggles
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App